LivaNova (NASDAQ:LIVN) Downgraded by StockNews.com to Buy

LivaNova (NASDAQ:LIVN) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Thursday.

Other equities analysts have also recently issued reports about the stock. The Goldman Sachs Group began coverage on shares of LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 price objective for the company. Mizuho reduced their price objective on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a research note on Monday, November 25th. Finally, Robert W. Baird boosted their target price on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, LivaNova has a consensus rating of “Buy” and an average price target of $69.17.

LivaNova Stock Down 1.1 %

NASDAQ LIVN opened at $48.65 on Thursday. The stock has a 50 day moving average price of $49.36 and a 200-day moving average price of $50.03. LivaNova has a one year low of $43.15 and a one year high of $64.47. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The company has a market capitalization of $2.64 billion, a P/E ratio of 115.83 and a beta of 1.01.

Insider Buying and Selling

In other news, Director Francesco Bianchi sold 1,250 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the transaction, the director now directly owns 7,522 shares in the company, valued at approximately $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.27% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On LivaNova

Large investors have recently added to or reduced their stakes in the stock. KBC Group NV raised its stake in shares of LivaNova by 130.5% during the fourth quarter. KBC Group NV now owns 99,928 shares of the company’s stock valued at $4,628,000 after acquiring an additional 56,580 shares in the last quarter. Harbor Capital Advisors Inc. purchased a new position in LivaNova during the 4th quarter worth $1,954,000. Diversified Trust Co raised its position in LivaNova by 9.5% during the 4th quarter. Diversified Trust Co now owns 16,432 shares of the company’s stock valued at $761,000 after purchasing an additional 1,425 shares in the last quarter. Nordea Investment Management AB raised its position in LivaNova by 22.2% during the 4th quarter. Nordea Investment Management AB now owns 68,711 shares of the company’s stock valued at $3,188,000 after purchasing an additional 12,470 shares in the last quarter. Finally, Central Pacific Bank Trust Division lifted its holdings in shares of LivaNova by 21.2% in the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after buying an additional 720 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.